AVASTIN 25 MG/ML PERF FL 4 ML
(Bevacizumab) - Maladie rare sans désignation orpheline
* In combination with interferon alfa-2a it is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.
* In combination with carboplatin and paclitaxel it is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
* In combination with carboplatin and gemcitabine, it is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary VEGF receptor–targeted agents.
* In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin it is indicated for the treatment of adult patients with platinumresistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
* In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent,recurrent, or metastatic carcinoma of the cervix.